About the Study

Acute Myeloid Leukemia (AML): A study of chemotherapy with or without venetoclax in children with relapsed AML without FLT3/ITD mutation

This study is for: • Patients who have enrolled in APAL2020SC • Who are greater than 28 days old to less than 22 years old • Who have been diagnosed with acute myeloid leukemia without FLT3/ITD mutation that has relapsed (has come back) This is a randomized trial (like the flip of a coin) to find what effects, good and/or bad, chemotherapy with venetoclax verus without venetoclax has on children and young adults with AML.

Interested in learning more?

Full Study Name: APAL2020D/ITCC-101